Lv1
30 积分 2025-06-02 加入
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
1小时前
待确认
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
18天前
已完结
PARP Inhibitors for Breast Cancer Treatment
21天前
已完结
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
21天前
已完结
Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer
2个月前
已完结
BCG therapy in bladder cancer and its tumor microenvironment interactions
2个月前
已完结
T-cell Engagers in Prostate Cancer
2个月前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
3个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
3个月前
已完结
皖公网安备34019202002308
